Literature DB >> 7490879

C-erbB-2 in bladder cancer: molecular biology, correlation with epidermal growth factor receptors and prognostic value.

J K Mellon1, J Lunec, C Wright, C H Horne, P Kelly, D E Neal.   

Abstract

PURPOSE: To study the c-erbB-2 oncogene in primary transitional cell bladder cancer.
MATERIALS AND METHODS: Ninety-five patients with known clinical follow-up and epidermal growth factor receptor (EGFr) status were studied for expression of c-erbB-2 by immunostaining. Possible mechanisms underlying increased staining for c-erbB-2 protein were investigated by analyzing DNA and RNA encoding c-erbB-2.
RESULTS: Strong positive staining for c-erbB-2 was detected in 20 (21%) tumors, with weaker staining in a further 13 (14%). There was no correlation between increased staining for c-erbB-2 and tumor stage, grade, or EGFr status. There was a low rate of amplification of the c-erbB-2 gene (1 of 24) on Southern blotting with a higher rate of elevated c-erbB-2 mRNA (4 of 44) with dot blot hybridization. For pT1 tumors, the rate of recurrence was higher for those tumors which were positive for c-erbB-2.
CONCLUSIONS: c-erbB-2 oncoprotein is expressed by a significant proportion of transitional cell tumors of the bladder. In this study, the prognostic significance of c-erbB-2 expression appears limited.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 7490879     DOI: 10.1016/s0022-5347(01)66653-9

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  23 in total

Review 1.  Epidermal growth factor receptor and bladder cancer.

Authors:  A J Colquhoun; J K Mellon
Journal:  Postgrad Med J       Date:  2002-10       Impact factor: 2.401

Review 2.  Molecular substratification of bladder cancer: moving towards individualized patient management.

Authors:  Anirban P Mitra
Journal:  Ther Adv Urol       Date:  2016-03-28

Review 3.  What we could do now: molecular pathology of bladder cancer.

Authors:  M A Knowles
Journal:  Mol Pathol       Date:  2001-08

4.  Involvement of HER-2/neu and metastasis-related proteins in the development of ileal neuroendocrine tumors.

Authors:  Cinzia Azzoni; Lorena Bottarelli; Stefano Cecchini; Costanza Lagrasta; Silvia Pizzi; Tiziana D'Adda; Elisa Tamburini; Guido Rindi; Cesare Bordi
Journal:  Virchows Arch       Date:  2011-03-29       Impact factor: 4.064

Review 5.  Role of anti-Her-2 therapy in bladder carcinoma.

Authors:  Alvaro Pinto Marín; Enrique Espinosa Arranz; Andrés Redondo Sánchez; Pilar Zamora Auñón; Manuel González Barón
Journal:  J Cancer Res Clin Oncol       Date:  2010-03-06       Impact factor: 4.553

6.  Human epidermal growth factor receptor 2 expression in urothelial carcinoma of the renal pelvis: correlation with clinicopathologic parameters.

Authors:  Laleh Ehsani; Adeboye O Osunkoya
Journal:  Int J Clin Exp Pathol       Date:  2014-04-15

7.  Relationship of PCNA, C-erbB2 and CD44s expression with tumor grade and stage in urothelial carcinomas of the bladder.

Authors:  Ayhan Yıldırım; Mustafa Kösem; Ilyas Sayar; Ibrahim Gelincik; Alparslan Yavuz; Aliseydi Bozkurt; Unal Erkorkmaz; Irfan Bayram
Journal:  Int J Clin Exp Med       Date:  2014-06-15

8.  Differential c-erbB-1 and c-erbB-2 mRNA expression in cancer of the pancreas compared with cancer of the papilla of Vater.

Authors:  Klaus L Prenzel; Ute Warnecke-Eberz; Jan Brabender; Stephan E Baldus; Elfriede Bollschweiler; Christian A Gutschow; Uta Drebber; Arnulf H Hoelscher; Paul M Schneider
Journal:  World J Gastroenterol       Date:  2006-01-21       Impact factor: 5.742

Review 9.  Growth factors and receptors as prognostic markers in urothelial carcinoma.

Authors:  Peter C Black; Colin P N Dinney
Journal:  Curr Urol Rep       Date:  2008-01       Impact factor: 3.092

10.  Targeted therapies in the management of metastatic bladder cancer.

Authors:  Matteo Fassan; Edouard J Trabulsi; Leonard G Gomella; Raffaele Baffa
Journal:  Biologics       Date:  2007-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.